AltruBio Gathers Funds as Biotechs Aim for Next Blockbuster Anti-Inflammatory Therapy

Biotechnology startup AltruBio has secured fresh capital to develop a drug for ulcerative colitis as drugmakers compete to develop the next blockbuster therapy for this and other inflammatory diseases.

Immunological and inflammatory diseases are common and not all patients respond to existing treatments. The inflammatory bowel diseases ulcerative colitis and Crohn’s disease, for example, affected an estimated three million U.S. adults in 2015, according to the Centers for Disease Control and Prevention.